Mga Batayang Estadistika
| CIK | 1581987 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Tigenix Sa
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 16, 2018 |
15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-37965 TiGenix (Exact name of registrant as specified in its chart |
|
| July 31, 2018 |
TGXSF / Tigenix Sa AMENDMENT NO. 12 TO SCHEDULE 14D-9 Amendment No. 12 to Schedule 14D-9 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. 12 TiGenix (Name of Subject Company) TiGenix (Name of Person(s) Filing Statement) Ordinary shares, no nominal value (“Shares”) American Depositary Shares (“ADSs”), |
|
| July 31, 2018 |
TGXSF / Tigenix Sa 6-K (Current Report of Foreign Issuer) 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2018 Commission File Number 001-37965 TiGenix Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or wil |
|
| July 31, 2018 |
Takeda Completes its Acquisition of TiGenix Following Expiration of the Squeeze-out Period EX-99.1 Exhibit 99.1 PRESS RELEASE Takeda Completes its Acquisition of TiGenix Following Expiration of the Squeeze-out Period ● TiGenix becomes a wholly owned subsidiary of Takeda ● Ordinary Shares have been delisted from Euronext Brussels ● The ADSs have been delisted from Nasdaq and TiGenix plans to terminate the ADS Facility and suspend its U.S. reporting obligations Osaka, Japan and Leuven, Be |
|
| July 31, 2018 |
Takeda Completes its Acquisition of TiGenix Following Expiration of the Squeeze-out Period EX-99.(A)(1)(XXVI) Exhibit (a)(1)(xxvi) PRESS RELEASE Takeda Completes its Acquisition of TiGenix Following Expiration of the Squeeze-out Period • TiGenix becomes a wholly owned subsidiary of Takeda • Ordinary Shares have been delisted from Euronext Brussels • The ADSs have been delisted from Nasdaq and TiGenix plans to terminate the ADS Facility and suspend its U.S. reporting obligations Osaka, J |
|
| July 31, 2018 |
TKPYY / Takeda Pharmaceutical Co., Ltd. AMENDMENT NO. 9 TO SCHEDULE TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 9) TiGenix (Name of Subject Company (Issuer)) TAKEDA PHARMACEUTICAL COMPANY LIMITED (Name of Filing Persons (Offeror)) Ordinary Shares, no nominal value (“Ordinary Shares”) American Depositary shares (“AD |
|
| July 26, 2018 |
TGXSF / Tigenix Sa AMENDMENT NO. 11 TO SCHEDULE 14D-9 Amendment No. 11 to Schedule 14D-9 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. 11 TiGenix (Name of Subject Company) TiGenix (Name of Person(s) Filing Statement) Ordinary shares, no nominal value (“Shares”) American Depositary Shares (“ADSs”), |
|
| July 26, 2018 |
TKPYY / Takeda Pharmaceutical Co., Ltd. AMENDMENT NO. 8 TO SCHEDULE TO SC TO-T/A 1 d573786dsctota.htm AMENDMENT NO. 8 TO SCHEDULE TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 8) TiGenix (Name of Subject Company (Issuer)) TAKEDA PHARMACEUTICAL COMPANY LIMITED (Name of Filing Persons (Offeror)) Ordinary Shares, no nom |
|
| July 26, 2018 |
TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer) 6-K 1 f6k072318.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2018 Commission File Number: 001-37965 TiGenix (Translation of registrant's name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal ex |
|
| July 26, 2018 |
TiGenix: Transparency notification pursuant to Article 14 of the Law of May 2, 2007 EXHIBIT 99.1 TiGenix: Transparency notification pursuant to Article 14 of the Law of May 2, 2007 REGULATED INFORMATION PRESS RELEASE Transparency notification pursuant to Article 14 of the Law of May 2, 2007 Leuven (Belgium) - July 23, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix") announced today that it received a transparency notification pursuant to Article 14 of |
|
| July 16, 2018 |
25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-37965 TiGenix (The Nasdaq Stock Market LLC) (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered) Romeinse stra |
|
| July 13, 2018 |
TGXSF / Tigenix Sa AMENDMENT NO. 10 TO SCHEDULE 14D-9 Amendment No. 10 to Schedule 14D-9 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. 10 TiGenix (Name of Subject Company) TiGenix (Name of Person(s) Filing Statement) Ordinary shares, no nominal value (“Shares”) American Depositary Shares (“ADSs”), |
|
| July 13, 2018 |
TGXSF / Tigenix Sa 6-K (Current Report of Foreign Issuer) 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2018 Commission File Number 001-37965 TiGenix Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or wil |
|
| July 13, 2018 |
Q&A in respect of Takeda’s intention to acquire TiGenix July 13, 2018 EX-99.1 Exhibit 99.1 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO, OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION. Q&A in respect of Takeda’s intention to acquire TiGenix July 13, 2018 A. DEAL RATIONALE AND TERMS 1. Why is Takeda acquiring TiGenix? We cannot comment on Takeda’s strategy. Information abou |
|
| July 6, 2018 |
TGXSF / Tigenix Sa AMENDMENT NO. 9 TO SCHEDULE 14D-9 SC 14D9/A 1 d909624dsc14d9a.htm AMENDMENT NO. 9 TO SCHEDULE 14D-9 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. 9 TiGenix (Name of Subject Company) TiGenix (Name of Person(s) Filing Statement) Ordinary shares, no nominal value (“Shares”) Americ |
|
| July 6, 2018 |
TKPYY / Takeda Pharmaceutical Co., Ltd. AMENDMENT NO. 7 TO SCHEDULE TO SC TO-T/A 1 d573786dsctota.htm AMENDMENT NO. 7 TO SCHEDULE TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 7) TiGenix (Name of Subject Company (Issuer)) TAKEDA PHARMACEUTICAL COMPANY LIMITED (Name of Filing Persons (Offeror)) Ordinary Shares, no nom |
|
| July 6, 2018 |
EX-99.(A)(1)(XXV) 2 d573786dex99a1xxv.htm EX-99.(A)(1)(XXV) Exhibit (a)(1)(xxv) PRESS RELEASE Takeda and TiGenix Announce Results of Second Acceptance Period for the Voluntary and Conditional Public Takeover Bid in respect of TiGenix and Commencement of Simplified Squeeze-out and Intention to Delist the ADSs from Nasdaq, Terminate the ADS Facility and Terminate TiGenix’s U.S. Reporting Obligations |
|
| July 6, 2018 |
TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2018 Commission File Number: 001-37965 TiGenix (Translation of registrant's name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by c |
|
| July 6, 2018 |
EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Takeda and TiGenix Announce Results of Second Acceptance Period for the Voluntary and Conditional Public Takeover Bid PRESS RELEASE Takeda and TiGenix Announce Results of Second Acceptance Period for the Voluntary and Conditional Public Takeover Bid in respect of TiGenix and Commencement of Simplified Squeeze-out and Intention to Delist the ADSs from |
|
| July 3, 2018 |
TGXSF / Tigenix Sa AMENDMENT NO. 8 TO SCHEDULE 14D-9 Amendment No. 8 to Schedule 14D-9 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. 8 TiGenix (Name of Subject Company) TiGenix (Name of Person(s) Filing Statement) Ordinary shares, no nominal value (“Shares”) American Depositary Shares (“ADSs”), e |
|
| July 3, 2018 |
TKPYY / Takeda Pharmaceutical Co., Ltd. AMENDMENT NO. 6 TO SCHEDULE TO Amendment No. 6 to Schedule TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 6) TiGenix (Name of Subject Company (Issuer)) TAKEDA PHARMACEUTICAL COMPANY LIMITED (Name of Filing Persons (Offeror)) Ordinary Shares, no nominal value (“Ordinary Shares”) |
|
| July 3, 2018 |
TiGenix: Transparency Information EXHIBIT 99.1 TiGenix: Transparency Information PRESS RELEASE REGULATED INFORMATION Transparency Information Leuven (Belgium) - July 2, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG) publishes information in accordance with articles 15 and 18 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regu |
|
| July 3, 2018 |
TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2018 Commission File Number: 001-37965 TiGenix (Translation of registrant's name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by c |
|
| June 29, 2018 |
TGXSF / Tigenix Sa 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2018 Commission File Number: 001-37965 TiGenix (Translation of registrant’s name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by |
|
| June 29, 2018 |
Transparency notification pursuant to Article 14 of the Law of May 2, 2007 Exhibit 99.1 REGULATED INFORMATION PRESS RELEASE Transparency notification pursuant to Article 14 of the Law of May 2, 2007 Leuven (Belgium) — June 27, 2018, 22:00h CET — TiGenix NV (Euronext Brussels and Nasdaq: TIG; “TiGenix”) announced today that it received a transparency notification pursuant to Article 14 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuer |
|
| June 29, 2018 |
TGXSF / Tigenix Sa 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 2018 Commission File Number: 001-37965 TiGenix (Translation of registrant’s name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark wheth |
|
| June 29, 2018 |
Transparency notification pursuant to Article 14 of the Law of May 2, 2007 Exhibit 99.1 REGULATED INFORMATION PRESS RELEASE Transparency notification pursuant to Article 14 of the Law of May 2, 2007 Leuven (Belgium) — June 22, 2018, 22:00h CET — TiGenix NV (Euronext Brussels and Nasdaq: TIG; “TiGenix”) announced today that it received a transparency notification pursuant to Article 14 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuer |
|
| June 28, 2018 |
TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2018 Commission File Number: 001-37965 TiGenix (Translation of registrant's name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by c |
|
| June 28, 2018 |
TiGenix: Transparency notification pursuant to Article 14 of the Law of May 2, 2007 EXHIBIT 99.1 TiGenix: Transparency notification pursuant to Article 14 of the Law of May 2, 2007 REGULATED INFORMATION PRESS RELEASE Transparency notification pursuant to Article 14 of the Law of May 2, 2007 Leuven (Belgium) - June 27, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix") announced today that it received a transparency notification pursuant to Article 14 of |
|
| June 25, 2018 |
TiGenix: Transparency notification pursuant to Article 14 of the Law of May 2, 2007 EXHIBIT 99.1 TiGenix: Transparency notification pursuant to Article 14 of the Law of May 2, 2007 REGULATED INFORMATION PRESS RELEASE Transparency notification pursuant to Article 14 of the Law of May 2, 2007 Leuven (Belgium) - June 22, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix") announced today that it received a transparency notification pursuant to Article 14 of |
|
| June 25, 2018 |
TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 2018 Commission File Number: 001-37965 TiGenix (Translation of registrant's name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether |
|
| June 20, 2018 |
TGXSF / Tigenix Sa AMENDMENT NO. 7 TO SCHEDULE 14D-9 Amendment No. 7 to Schedule 14D-9 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. 7 TiGenix (Name of Subject Company) TiGenix (Name of Person(s) Filing Statement) Ordinary shares, no nominal value (“Shares”) American Depositary Shares (“ADSs”), e |
|
| June 20, 2018 |
TGXSF / Tigenix Sa 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2018 Commission File Number 001-37965 TiGenix Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or will fi |
|
| June 20, 2018 |
Q&A in respect of Takeda’s intention to acquire TiGenix June 20, 2018 Exhibit 99.1 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO, OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION. Q&A in respect of Takeda’s intention to acquire TiGenix June 20, 2018 A. DEAL RATIONALE AND TERMS 1. Why does Takeda intend to acquire TiGenix? We cannot comment on Takeda’s strategy. Information ab |
|
| June 20, 2018 |
TiGenix: Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 EXHIBIT 99.1 TiGenix: Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 REGULATED INFORMATION PRESS RELEASE Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 Leuven (Belgium) - June 19, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix") announced today that it received transparency notifications pursuant to Article 14 of |
|
| June 20, 2018 |
TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 2018 Commission File Number: 001-37965 TiGenix (Translation of registrant's name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether |
|
| June 19, 2018 |
ARDM / Aradigm Corp. / Grifols SA - SC 13D/A Activist Investment SC 13D/A 1 a18-155291sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* TiGenix (Name of Issuer) Ordinary shares, no nominal value per share (Title of Class of Securities) 88675R 10 9 (CUSIP Number) Grifols, S.A. Avinguda de la Generalitat, 152-158 Parc de Negocis Can Sant Joan Sant |
|
| June 18, 2018 |
Transparency notification pursuant to Article 14 of the Law of May 2, 2007 EXHIBIT 99.1 Transparency notification pursuant to Article 14 of the Law of May 2, 2007 REGULATED INFORMATION PRESS RELEASE Transparency notification pursuant to Article 14 of the Law of May 2, 2007 Leuven (Belgium) - June 14, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix") announced today that it received a transparency notification pursuant to Article 14 of the Belgi |
|
| June 18, 2018 |
TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer) 6-K 1 f6k061418.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 2018 Commission File Number: 001-37965 TiGenix (Translation of registrant's name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) I |
|
| June 13, 2018 |
TGXSF / Tigenix Sa AMENDMENT NO. 6 TO SCHEDULE 14D-9 Amendment No. 6 to Schedule 14D-9 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. 6 TiGenix (Name of Subject Company) TiGenix (Name of Person(s) Filing Statement) Ordinary shares, no nominal value (“Shares”) American Depositary Shares (“ADSs”), e |
|
| June 13, 2018 |
TiGenix announces a change in its Board of Directors and its Management Team EXHIBIT 99.1 TiGenix announces a change in its Board of Directors and its Management Team PRESS RELEASE REGULATED INFORMATION INSIDE INFORMATION TiGenix announces a change in its Board of Directors and its Management Team Leuven (Belgium) - June 13, 2018, 07:00h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory |
|
| June 13, 2018 |
TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 2018 Commission File Number: 001-37965 TiGenix (Translation of registrant's name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether |
|
| June 6, 2018 |
TGXSF / Tigenix Sa AMENDMENT NO. 5 TO SCHEDULE 14D-9 SC 14D9/A 1 d575212dsc14d9a.htm AMENDMENT NO. 5 TO SCHEDULE 14D-9 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. 5 TiGenix (Name of Subject Company) TiGenix (Name of Person(s) Filing Statement) Ordinary shares, no nominal value (“Shares”) Americ |
|
| June 6, 2018 |
TKPYY / Takeda Pharmaceutical Co., Ltd. AMENDMENT NO. 5 TO SCHEDULE TO Amendment No. 5 to Schedule TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 5) TiGenix (Name of Subject Company (Issuer)) TAKEDA PHARMACEUTICAL COMPANY LIMITED (Name of Filing Persons (Offeror)) Ordinary Shares, no nominal value (“Ordinary Shares”) |
|
| June 6, 2018 |
EX-99.(A)(1)(XXIV) 3 d573786dex99a1xxiv.htm EX-99.(A)(1)(XXIV) Exhibit (a)(1)(xxiv) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Ordinary Shares and/or ADSs (both, as defined below). The U.S. Offer (as defined below) is being made pursuant to the U.S. Offer to Purchase (as defined below), the related share acceptance letter, the related ADS letter of tra |
|
| June 6, 2018 |
EX-99.(A)(1)(XXIII) 2 d573786dex99a1xxiii.htm EX-99.(A)(1)(XXIII) Exhibit (a)(1)(xxiii) Takeda and TiGenix Announce Results of First Acceptance Period for the Voluntary and Conditional Public Takeover Bid of TiGenix and Commencement of Second Acceptance Period • The number of Securities tendered into the Bid, together with all Securities owned by Takeda and its affiliates, represents or gives acce |
|
| June 6, 2018 |
TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2018 Commission File Number: 001-37965 TiGenix (Translation of registrant's name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by c |
|
| June 6, 2018 |
EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Takeda and TiGenix Announce Results of First Acceptance Period for the Voluntary and Conditional Public Takeover Bid of TiGenix and Commencement of Second Acceptance Period PRESS RELEASE REGULATED INFORMATION INSIDE INFORMATION Takeda and TiGenix Announce Results of First Acceptance Period for the Voluntary and Conditional Public Takeover Bid of TiGe |
|
| May 31, 2018 |
TGXSF / Tigenix Sa AMENDMENT NO. 4 TO SCHEDULE 14D-9 SC 14D9/A 1 d597279dsc14d9a.htm AMENDMENT NO. 4 TO SCHEDULE 14D-9 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. 4 TiGenix (Name of Subject Company) TiGenix (Name of Person(s) Filing Statement) Ordinary shares, no nominal value (“Shares”) Americ |
|
| May 31, 2018 |
TKPYY / Takeda Pharmaceutical Co., Ltd. AMENDMENT NO. 4 TO SCHEDULE TO SC TO-T/A 1 d573786dsctota.htm AMENDMENT NO. 4 TO SCHEDULE TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 4) TiGenix (Name of Subject Company (Issuer)) TAKEDA PHARMACEUTICAL COMPANY LIMITED (Name of Filing Persons (Offeror)) Ordinary Shares, no nom |
|
| May 30, 2018 |
TiGenix: Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 EXHIBIT 99.1 TiGenix: Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 REGULATED INFORMATION PRESS RELEASE Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 Leuven (Belgium) - May 28, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix") announced today that it received transparency notifications pursuant to Article 14 of |
|
| May 30, 2018 |
TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 2018 Commission File Number: 001-37965 TiGenix (Translation of registrant's name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether |
|
| May 23, 2018 |
TGXSF / Tigenix Sa AMENDMENT NO. 3 TO SCHEDULE 14D-9 Amendment No. 3 to Schedule 14D-9 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. 3 TiGenix (Name of Subject Company) TiGenix (Name of Person(s) Filing Statement) Ordinary shares, no nominal value (“Shares”) American Depositary Shares (“ADSs”), e |
|
| May 23, 2018 |
TKPYY / Takeda Pharmaceutical Co., Ltd. AMENDMENT NO. 3 TO SCHEDULE TO SC TO-T/A 1 d573786dsctota.htm AMENDMENT NO. 3 TO SCHEDULE TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) TiGenix (Name of Subject Company (Issuer)) TAKEDA PHARMACEUTICAL COMPANY LIMITED (Name of Filing Persons (Offeror)) Ordinary Shares, no nom |
|
| May 23, 2018 |
EX-99.(A)(1)(XXII) 2 d573786dex99a1xxii.htm EX-99.(A)(1)(XXII) Exhibit (a)(1)(xxii) News Release Takeda Announces Information Related to its Pending Voluntary and Conditional Public Takeover Bid for Outstanding Shares and American Depositary Shares of TiGenix Osaka, Japan, May 23, 2018 – Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today announced information related to its previou |
|
| May 18, 2018 |
TGXSF / Tigenix Sa AMENDMENT NO. 2 TO SCHEDULE 14D-9 Amendment No. 2 to Schedule 14D-9 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. 2 TiGenix (Name of Subject Company) TiGenix (Name of Person(s) Filing Statement) Ordinary shares, no nominal value (“Shares”) American Depositary Shares (“ADSs”), e |
|
| May 18, 2018 |
TKPYY / Takeda Pharmaceutical Co., Ltd. AMENDMENT NO. 2 TO SCHEDULE TO SC TO-T/A 1 d573786dsctota.htm AMENDMENT NO. 2 TO SCHEDULE TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) TiGenix (Name of Subject Company (Issuer)) TAKEDA PHARMACEUTICAL COMPANY LIMITED (Name of Filing Persons (Offeror)) Ordinary Shares, no nom |
|
| May 16, 2018 |
TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer) 6-K 1 f6k051418.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2018 Commission File Number: 001-37965 TiGenix (Translation of registrant's name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal exe |
|
| May 16, 2018 |
TiGenix:Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 EXHIBIT 99.1 TiGenix:Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 REGULATED INFORMATION PRESS RELEASE Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 Leuven (Belgium) - May 14, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix") announced today that it received transparency notifications pursuant to Article 14 of t |
|
| May 11, 2018 |
TGXSF / Tigenix Sa AMENDMENT NO. 1 TO SCHEDULE 14D-9 Amendment No. 1 to Schedule 14D-9 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. 1 TiGenix (Name of Subject Company) TiGenix (Name of Person(s) Filing Statement) Ordinary shares, no nominal value (“Shares”) American Depositary Shares (“ADSs”), e |
|
| May 11, 2018 |
TKPYY / Takeda Pharmaceutical Co., Ltd. AMENDMENT NO. 1 TO SCHEDULE TO Amendment No. 1 to Schedule TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) TiGenix (Name of Subject Company (Issuer)) TAKEDA PHARMACEUTICAL COMPANY LIMITED (Name of Filing Persons (Offeror)) Ordinary Shares, no nominal value (“Ordinary Shares”) |
|
| May 11, 2018 |
20-F/A 1 a18-11226120fa.htm 20-F/A As filed with the Securities and Exchange Commission on May 11, 2018 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F/A Amendment No. 1 (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 |
|
| May 8, 2018 |
TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2018 Commission File Number: 001-37965 TiGenix (Translation of registrant's name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by ch |
|
| May 8, 2018 |
EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 TiGenix: CONVENING NOTICE TO THE ANNUAL SHAREHOLDERS' MEETING TO BE HELD ON 7 JUNE 2018 TiGenix Limited liability company that makes or has made a public call on savings Romeinse straat 12 box 2 3001 Leuven VAT BE 0471.340.123 RLE Leuven CONVENING NOTICE TO the ANNUAL shareholders' meeting to be held on 7 JUNE 2018 The board of directors of TiGenix N |
|
| April 30, 2018 |
SC 14D9 Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 TiGenix (Name of Subject Company) TiGenix (Name of Person(s) Filing Statement) Ordinary shares, no nominal value (“Shares”) American Depositary Shares (“ADSs”), each representing 20 Shar |
|
| April 30, 2018 |
EX-99.(A)(1)(VII) 8 d573786dex99a1vii.htm EX-99.(A)(1)(VII) Exhibit (a)(1)(vii) U.S. OFFER TO PURCHASE FOR CASH ALL OUTSTANDING ORDINARY SHARES HELD BY U.S. HOLDERS AND ALL OUTSTANDING AMERICAN DEPOSITARY SHARES REPRESENTING ORDINARY SHARES, HELD BY ALL HOLDERS, WHEREVER LOCATED OF TIGENIX FOR € 1.78 PER ORDINARY SHARE AND € 35.60 PER AMERICAN DEPOSITARY SHARE, PAYABLE IN U.S. DOLLARS, BY TAKEDA P |
|
| April 30, 2018 |
Form of Share Acceptance Letter.* EX-99.(A)(1)(II) 3 d573786dex99a1ii.htm EX-99.(A)(1)(II) Exhibit (a)(1)(ii) SHARE ACCEPTANCE LETTER ACCEPTANCE LETTER FOR THE U.S. OFFER TO PURCHASE FOR CASH ALL OUTSTANDING ORDINARY SHARES HELD BY U.S. HOLDERS OF TIGENIX NV FOR €1.78 PER SHARE, WITHOUT INTEREST, BY TAKEDA PHARMACEUTICAL COMPANY LIMITED Acceptance Letter for Ordinary Shares only ANY U.S. Holder of Ordinary Shares in book-entry for |
|
| April 30, 2018 |
Form of Notice of Guaranteed Delivery.* EX-99.(A)(1)(V) Exhibit (a)(1)(v) NOTICE OF GUARANTEED DELIVERY TO TENDER FOR CASH AMERICAN DEPOSITARY SHARES REPRESENTING ORDINARY SHARES OF TIGENIX NV BY TAKEDA PHARMACEUTICAL COMPANY LIMITED PURSUANT TO THE U.S. OFFER TO PURCHASE DATED APRIL 30, 2018 THE U.S. OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 10:00 A.M., NEW YORK CITY TIME, ON MAY 31, 2018, UNLESS THE U.S. OFFER IS EXTENDED. Delivery o |
|
| April 30, 2018 |
SECOND ADDENDUM TO CONFIDENTIAL DISCLOSURE AGREEMENT EX-99.(d)(3) Exhibit (d)(3) SECOND ADDENDUM TO CONFIDENTIAL DISCLOSURE AGREEMENT This addendum (the “Second Addendum”) is made effective as of the date of the last signature hereto by and between: 1. TiGenix SAU, with registered office at Calle Marconi 1, Parque Tecnológico de Madrid, 28760 Tres Cantos, Madrid, Spain, registered with the Commercial Registry of Madrid under volume number 20117, pag |
|
| April 30, 2018 |
EX-99.(A)(1)(VIII) Exhibit (a)(1)(viii) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Ordinary Shares and/or ADSs (both, as defined below). The U.S. Offer (as defined below) is made only by the U.S. Offer to Purchase, dated April 30, 2018, the related Share Acceptance Letter, the related ADS Letter of Transmittal and the related Share Withdrawal Letter an |
|
| April 30, 2018 |
Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.* EX-99.(A)(1)(VI) Exhibit (a)(1)(vi) U.S. OFFER TO PURCHASE FOR CASH ALL OUTSTANDING ORDINARY SHARES HELD BY U.S. HOLDERS AND ALL OUTSTANDING AMERICAN DEPOSITARY SHARES REPRESENTING ORDINARY SHARES, HELD BY ALL HOLDERS, WHEREVER LOCATED OF TIGENIX FOR € 1.78 PER ORDINARY SHARE AND € 35.60 PER AMERICAN DEPOSITARY SHARE, PAYABLE IN U.S. DOLLARS, BY TAKEDA PHARMACEUTICAL COMPANY LIMITED THE U.S. OFFER |
|
| April 30, 2018 |
TKPYY / Takeda Pharmaceutical Co., Ltd. SC TO-T SC TO-T 1 d573786dsctot.htm SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 TiGenix (Name of Subject Company (Issuer)) TAKEDA PHARMACEUTICAL COMPANY LIMITED (Name of Filing Persons (Offeror)) Ordinary Shares, no nominal value (“Ordinary Shares”) American Depo |
|
| April 30, 2018 |
EX-99.(A)(1)(III) Exhibit (a)(1)(iii) [Insert Bar Code] Tax ID certification on file: TOTAL AMERICAN DEPOSITARY SHARES (ADSs) 12345678901234 Letter of Transmittal to Tender American Depositary Shares (ADSs) THE U.S. OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 10:00 A.M., NEW YORK CITY TIME, ON MAY 31, 2018, UNLESS THE U.S. OFFER IS EXTENDED. If you hold ADSs through a bank, broker, dealer, commerci |
|
| April 30, 2018 |
EX-99.(d)(4) Exhibit (d)(4) Strictly Private & Confidential November 10, 2017 The Board of Directors TiGenix NV c/o TiGenix SAU Calle Marconi, I Parque Tecnológico de Madrid 28760 Tres Cantos Madrid, Spain FAO: Eduardo Bravo Managing Director and Chief Executive Officer Dear Eduardo, On behalf of Takeda Pharmaceutical Company Limited (“Takeda”, “we” or “us”), we thank you for the interactions we h |
|
| April 30, 2018 |
Form of Share Withdrawal Letter.* EX-99.(A)(1)(IV) 5 d573786dex99a1iv.htm EX-99.(A)(1)(IV) Exhibit (a)(1)(iv) SHARE WITHDRAWAL LETTER SHARE WITHDRAWAL LETTER FOR THE U.S. OFFER TO PURCHASE FOR CASH ALL OUTSTANDING ORDINARY SHARES HELD BY U.S. HOLDERS OF TIGENIX NV FOR €1.78 PER SHARE, WITHOUT INTEREST, BY TAKEDA PHARMACEUTICAL COMPANY LIMITED TO BE COMPLETED AND SUBMITTED IN DUPLICATE TO THE FINANCIAL INTERMEDIARY TO WHICH THE SHA |
|
| April 30, 2018 |
EX-99.(A)(1)(I) 2 d573786dex99a1i.htm EX-99.(A)(1)(I) Exhibit (a)(1)(i) U.S. OFFER TO PURCHASE FOR CASH ALL OUTSTANDING ORDINARY SHARES HELD BY U.S. HOLDERS AND ALL OUTSTANDING AMERICAN DEPOSITARY SHARES REPRESENTING ORDINARY SHARES, HELD BY ALL HOLDERS, WHEREVER LOCATED OF TIGENIX FOR €1.78 PER ORDINARY SHARE AND €35.60 PER AMERICAN DEPOSITARY SHARE, PAYABLE IN U.S. DOLLARS, BY TAKEDA PHARMACEUTI |
|
| April 27, 2018 |
SC14D9C 1 a18-123801sc14d9c.htm SC14D9C SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 TiGenix (Name of Subject Company) TiGenix (Name of Person(s) Filing Statement) Ordinary shares, no nominal value (“Shares”) American Depositary Shares (“ADSs”), each repres |
|
| April 27, 2018 |
EXHIBIT 99.1 TiGenix: Publication of prospectus and response memorandum for Takeda takeover bid commencing on April 30, 2018 PRESS RELEASE Publication of prospectus and response memorandum for Takeda takeover bid commencing on April 30, 2018 Leuven (BELGIUM) - April 27, 2018, 07:00h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG) ("TiGenix"), an advanced biopharmaceutical company focused on |
|
| April 27, 2018 |
TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2018 Commission File Number: 001-37965 TiGenix (Translation of registrant's name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by |
|
| April 27, 2018 |
TiGenix: Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 EXHIBIT 99.1 TiGenix: Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 REGULATED INFORMATION PRESS RELEASE Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 Leuven (Belgium) - April 26, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix") announced today that it received transparency notifications pursuant to Article 14 o |
|
| April 27, 2018 |
TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2018 Commission File Number: 001-37965 TiGenix (Translation of registrant's name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by |
|
| April 25, 2018 |
SC14D9C 1 a18-121991sc14d9c.htm SC14D9C SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 TiGenix (Name of Subject Company) TiGenix (Name of Person(s) Filing Statement) Ordinary shares, no nominal value (“Shares”) American Depositary Shares (“ADSs”), each repres |
|
| April 25, 2018 |
Q&A in respect of Takeda’s intention to acquire TiGenix April 25, 2018 EX-99.1 2 a18-121991ex99d1.htm EX-99.1 Exhibit 99.1 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO, OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION. Q&A in respect of Takeda’s intention to acquire TiGenix April 25, 2018 A. DEAL RATIONALE AND TERMS 1. Why does Takeda intend to acquire TiGenix? We cannot comm |
|
| April 25, 2018 |
EX-99.1 Exhibit 99.1 News Release Takeda Announces Voluntary and Conditional Public Takeover Bid for Outstanding Shares, Warrants and American Depositary Shares of TiGenix NV to Commence April 30, 2018 • Prospectus and response memorandum approved by the FSMA on April 24, 2018 and to be published on April 27, 2018 • Initial acceptance period will commence on April 30, 2018 and expire on May 31, 20 |
|
| April 25, 2018 |
TKPYY / Takeda Pharmaceutical Co., Ltd. SC TO-C SC TO-C 1 d574904dsctoc.htm SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 TiGenix (Name of Subject Company (Issuer)) TAKEDA PHARMACEUTICAL COMPANY LIMITED (Name of Filing Persons (Offeror)) Ordinary shares, no nominal value (“Shares”) American Deposit |
|
| April 16, 2018 |
EX-16.1 11 dp89495ex1601.htm EXHIBIT 16.1 Exhibit 16.1 April 16, 2018 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 United States of America We have been furnished with a copy of the response to Item 16F of Form 20-F for the event that occurred on June 1, 2017, to be filed by our former client, Tigenix NV. We agree with the statements made in response to that Item ins |
|
| April 16, 2018 |
Warrants Plan 2017 (English translation) Exhibit 4.25 ENGLISH TRANSLATION FOR INFORMATION PURPOSES ONLY TiGenix Naamloze vennootschap die een openbaar beroep op het spaarwezen doet of heeft gedaan Romeinse straat 12 box 2 3001 Leuven VAT BE 0471.340.123 RLE Leuven (the “Company”) Warrants plan 2017 1 Definitions For the purposes of this warrants plan 2017 (the “Plan”), the following terms shall have the following meaning: “Shares” means |
|
| April 16, 2018 |
Certification of Claudia D’Augusta pursuant to 17 CFR 240.13a-14(b) and 18 U.S.C.1350 Exhibit 13.2 CERTIFICATION The certification set forth below is being submitted in connection with TiGenix’s Annual Report on Form 20-F for the fiscal year ended December 31, 2017 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code. Claudia |
|
| April 16, 2018 |
Certification of Claudia D’Augusta pursuant to 17 CFR 240.13a-14(a) Exhibit 12.2 CERTIFICATION I, Claudia D’Augusta, certify that: 1. I have reviewed this annual report on Form 20-F of TiGenix; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the per |
|
| April 16, 2018 |
Articles of Association of TiGenix, as amended and currently in effect (English translation) EX-1.1 2 dp89495ex0101.htm EXHIBIT 1.1 Exhibit 1.1 Free English translation Coordinated text of the articles of association of Naamloze vennootschap die een openbaar beroep op het spaarwezen doet of gedaan heeft “TiGenix” with registered office at 3001 Leuven, Romeinse straat 12 box 2, enterprise number 0471.340.123 - RLE Leuven after the modification to the articles of association on 6 February 2 |
|
| April 16, 2018 |
As filed with the Securities and Exchange Commission on April 16, 2018 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 16, 2018 |
Certification of Eduardo Bravo pursuant to 17 CFR 240.13a-14(a) Exhibit 12.1 CERTIFICATION I, Eduardo Bravo, certify that: 1. I have reviewed this annual report on Form 20-F of TiGenix; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period |
|
| April 16, 2018 |
Exhibit 4.23 OFFER AND SUPPORT AGREEMENT BETWEEN 1. Takeda Pharmaceutical Company Limited, a company under the laws of Japan, having its registered office at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka, Japan, hereby validly represented by Misako Hirose, in her capacity as Authorised Representative, hereinafter referred to as the "Bidder" or "Takeda"; ON THE ONE HAND AND 2. TiGenix NV, a limited liabi |
|
| April 16, 2018 |
PATENT LICENSE AND SETTLEMENT AGREEMENT Exhibit 4.24 EXECUTION COPY ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under Rule 24b-2 under the Securities Exchange Act of 1934 PATENT LICENSE AND SETTLEMENT AGREEMENT This PATENT LICENSE AND SETTLEMENT AGREEMENT is entered into as of December 14, 2017 (the “Effective Date”) by and between, on the one hand, Mesoblast Inc., a |
|
| April 16, 2018 |
Certification of Eduardo Bravo pursuant to 17 CFR 240.13a-14(b) and 18 U.S.C.1350 Exhibit 13.1 CERTIFICATION The certification set forth below is being submitted in connection with TiGenix’s Annual Report on Form 20-F for the fiscal year ended December 31, 2017 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code. Eduardo |
|
| April 16, 2018 |
TiGenix: Transparency notification pursuant to Article 14 of the Law of May 2, 2007 EXHIBIT 99.1 TiGenix: Transparency notification pursuant to Article 14 of the Law of May 2, 2007 REGULATED INFORMATION PRESS RELEASE Transparency notification pursuant to Article 14 of the Law of May 2, 2007 Leuven (Belgium) - April 13, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix") announced today that it received a transparency notification pursuant to Article 14 of |
|
| April 16, 2018 |
TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 2018 Commission File Number: 001-37965 TiGenix (Translation of registrant's name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whethe |
|
| April 13, 2018 |
TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2018 Commission File Number: 001-37965 TiGenix (Translation of registrant's name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by |
|
| April 13, 2018 |
TiGenix: Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 EXHIBIT 99.1 TiGenix: Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 REGULATED INFORMATION PRESS RELEASE Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 Leuven (Belgium) - March 30, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix") announced today that it received transparency notifications pursuant to Article 14 o |
|
| April 12, 2018 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 TiGenix (Name of Subject Company) TiGenix (Name of Person(s) Filing Statement) Ordinary shares, no nominal value (“Shares”) American Depositary Shares (“ADSs”), each representing 20 Shares (Title of Class of Secu |
|
| April 12, 2018 |
TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer) 6-K 1 f6k041218.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2018 Commission File Number: 001-37965 TiGenix (Translation of registrant's name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal e |
|
| April 12, 2018 |
TiGenix reports 2017 full year results EX-99.1 2 exh991.htm EXHIBIT 99.1 EXHIBIT 99.1 TiGenix reports 2017 full year results PRESS RELEASE Regulated information inside information TiGenix reports 2017 full year results Leuven (BELGIUM) - April 12, 2018, 7:00h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived |
|
| April 12, 2018 |
TiGenix: Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 EXHIBIT 99.1 TiGenix: Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 REGULATED INFORMATION PRESS RELEASE Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 Leuven (Belgium) - April 10, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix") announced today that it received transparency notifications pursuant to Article 14 o |
|
| April 12, 2018 |
TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2018 Commission File Number: 001-37965 TiGenix (Translation of registrant's name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by |
|
| April 9, 2018 |
Extract from the minutes of the annual shareholders’ meeting dated June 1, 2017 EX-99.1 2 a18-98201ex99d1.htm EX-99.1 Exhibit 99.1 Extract from the minutes of the annual shareholders’ meeting dated June 1, 2017 Appointment of the statutory auditor and remuneration The shareholders’ meeting resolves to appoint PwC Bedrijfsrevisoren BCVBA, with registered office at Woluwedal 18, 1932 Sint-Stevens-Woluwe, Belgium, as statutory auditor. PwC Bedrijfsrevisoren BCVBA designated Marc |
|
| April 9, 2018 |
TGXSF / Tigenix Sa 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2017 Commission File Number 001-37965 TiGenix Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or will fi |
|
| March 23, 2018 |
EX-99.1 Exhibit 99.1 PRESS RELEASE REGULATED INFORMATION INSIDE INFORMATION TiGenix and Takeda announce Alofisel® (darvadstrocel) receives approval to treat complex perianal fistulas in Crohn’s disease in Europe • First allogeneic stem cell therapy to receive central marketing authorization approval in Europe • Alofisel offers a new treatment option for patients who do not respond to current avail |
|
| March 23, 2018 |
TKPYY / Takeda Pharmaceutical Co., Ltd. SC TO-C SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 TiGenix (Name of Subject Company (Issuer)) TAKEDA PHARMACEUTICAL COMPANY LIMITED (Name of Filing Persons (Offeror)) Ordinary shares, no nominal value (“Shares”) American Depositary Shares (“ADSs”), each re |
|
| March 23, 2018 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 TiGenix (Name of Subject Company) TiGenix (Name of Person(s) Filing Statement) Ordinary shares, no nominal value (“Shares”) American Depositary Shares (“ADSs”), each representing 20 Shares (Title of Class of Secu |
|
| March 23, 2018 |
Exhibit 99.1 PRESS RELEASE REGULATED INFORMATION INSIDE INFORMATION TiGenix and Takeda announce Alofisel® (darvadstrocel) receives approval to treat complex perianal fistulas in Crohn’s disease in Europe · First allogeneic stem cell therapy to receive central marketing authorization approval in Europe · Alofisel offers a new treatment option for patients who do not respond to current available the |
|
| March 23, 2018 |
TGXSF / Tigenix Sa 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2018 Commission File Number 001-37965 TiGenix Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or will f |
|
| February 16, 2018 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 TiGenix (Name of Subject Company) TiGenix (Name of Person(s) Filing Statement) Ordinary shares, no nominal value (Shares) American Depositary Shares (ADSs), each representing 20 Shares (Title of Class of Secu |
|
| February 16, 2018 |
Q&A in respect of Takeda?s intention to acquire TiGenix February 16, 2018 Exhibit 99.1 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO, OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION. Q&A in respect of Takeda?s intention to acquire TiGenix February 16, 2018 A. DEAL RATIONALE AND TERMS 1. Why does Takeda intend to acquire TiGenix? We cannot comment on Takeda?s strategy. 2. Why is |
|
| February 15, 2018 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 TiGenix (Name of Subject Company) TiGenix (Name of Person(s) Filing Statement) Ordinary shares, no nominal value (?Shares?) American Depositary Shares (?ADSs?), each representing 20 Shares (Title of Class of Secu |
|
| February 15, 2018 |
Exhibit 99.1 Courtesy translation For information purposes only February 15, 2018 NOTICE PUBLISHED BY THE FSMA IN ACCORDANCE WITH ARTICLE 7 OF THE ROYAL DECREE OF 27 APRIL 2007 ON PUBLIC TAKEOVER BIDS The FSMA publishes, in accordance with article 7, section 1 of the Royal Decree of 27 April 2007 on public takeover bids, the notice it received, in accordance with article 5 of the aforementioned Ro |
|
| February 15, 2018 |
TGXSF / Tigenix Sa 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2018 Commission File Number 001-37965 TiGenix Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or wil |
|
| February 15, 2018 |
TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2018 Commission File Number: 001-37965 TiGenix (Translation of registrant's name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate |
|
| February 15, 2018 |
TiGenix: Transparency Information EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 TiGenix: Transparency Information PRESS RELEASE REGULATED INFORMATION Transparency Information Leuven (BELGIUM) - February 6, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG) publishes information in accordance with articles 15 and 18 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose secur |
|
| February 14, 2018 |
TGXSF / Tigenix Sa / Cormorant Asset Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* TiGenix NV (Name of Issuer) Ordinary Shares, no par value per share (Title of Class of Securities) 88675R109 (CUSIP Number) December 31, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 12, 2018 |
* * * Transcript of Video Message EX-99.1 Exhibit 99.1 Disclaimer This communication does not constitute an offer to purchase securities of TiGenix nor a solicitation by anyone in any jurisdiction in respect of such securities, any vote or approval. If Takeda decides to proceed with an offer to purchase TiGenix?s securities through a public tender offer, such offer will and can only be made on the basis of an approved offer docume |
|
| February 12, 2018 |
TKPYY / Takeda Pharmaceutical Co., Ltd. SC TO-C SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 TiGenix (Name of Subject Company (Issuer)) TAKEDA PHARMACEUTICAL COMPANY LIMITED (Name of Filing Persons (Offeror)) Ordinary shares, no nominal value (?Shares?) American Depositary Shares (?ADSs?), each re |
|
| February 1, 2018 |
Takeda Pharmaceutical Company Limited (4502) EX-99.3 Exhibit 99.3 Takeda Pharmaceutical Company Limited (4502) Summary of Financial Statements for the Nine Month Period Ended December 31, 2017 (Consolidated) (Significant Subsequent Events) Intention to acquire TiGenix NV On January 5, 2018, Takeda entered into an offer and support agreement with TiGenix NV (Euronext Brussels and NASDAQ: TIG) (TiGenix), an advanced biopharmaceutical company |
|
| February 1, 2018 |
TKPYY / Takeda Pharmaceutical Co., Ltd. SC TO-C SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 TiGenix (Name of Subject Company (Issuer)) TAKEDA PHARMACEUTICAL COMPANY LIMITED (Name of Filing Persons (Offeror)) Ordinary shares, no nominal value (?Shares?) American Depositary Shares (?ADSs?), each re |
|
| February 1, 2018 |
Better Health, Brighter Future EX-99.1 Exhibit 99.1 Better Health, Brighter Future Consolidated Financial Results for FY2017 Q3 February 1, 2018 James Kehoe Chief Financial Officer Takeda Pharmaceutical Company Limited Important Notice Forward-Looking Statements This presentation contains forward-looking statements regarding Takedas future business, financial position and results of operations, including estimates, forecasts, |
|
| February 1, 2018 |
EX-99.2 Exhibit 99.2 Disclaimer This communication does not constitute an offer to purchase securities of TiGenix nor a solicitation by anyone in any jurisdiction in respect of such securities, any vote or approval. If Takeda decides to proceed with an offer to purchase TiGenixs securities through a public tender offer, such offer will and can only be made on the basis of an approved offer docume |
|
| January 31, 2018 |
TiGenix: Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 TiGenix: Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 REGULATED INFORMATION PRESS RELEASE Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 Leuven (Belgium) - January 31, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix") announced today that it received transparency n |
|
| January 31, 2018 |
TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 2018 Commission File Number: 001-37965 TiGenix (Translation of registrant's name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whet |
|
| January 29, 2018 |
TiGenix:Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 EdgarFiling EXHIBIT 99.1 TiGenix:Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 REGULATED INFORMATION PRESS RELEASE Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 Leuven (Belgium) - January 26, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix") announced today that it received transparency notifications pursuant to |
|
| January 29, 2018 |
TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2018 Commission File Number: 001-37965 TiGenix (Translation of registrant's name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate b |
|
| January 26, 2018 |
TKPYY / Takeda Pharmaceutical Co., Ltd. SC TO-C SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 TiGenix (Name of Subject Company (Issuer)) TAKEDA PHARMACEUTICAL COMPANY LIMITED (Name of Filing Persons (Offeror)) Ordinary shares, no nominal value (?Shares?) American Depositary Shares (?ADSs?), each re |
|
| January 26, 2018 |
EX-99.1 Exhibit 99.1 Disclaimer This communication does not constitute an offer to purchase securities of TiGenix nor a solicitation by anyone in any jurisdiction in respect of such securities, any vote or approval. If Takeda decides to proceed with an offer to purchase TiGenixs securities through a public tender offer, such offer will and can only be made on the basis of an approved offer docume |
|
| January 22, 2018 |
TiGenix: Transparency Information EdgarFiling EXHIBIT 99.1 TiGenix: Transparency Information PRESS RELEASE REGULATED INFORMATION Transparency Information Leuven (BELGIUM) - January 19, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG) publishes information in accordance with articles 15 and 18 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to t |
|
| January 22, 2018 |
TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2018 Commission File Number: 001-37965 TiGenix (Translation of registrant's name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate b |
|
| January 22, 2018 |
TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2018 Commission File Number: 001-37965 TiGenix (Translation of registrant's name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate b |
|
| January 22, 2018 |
TiGenix: Transparency notification pursuant to Article 14 of the Law of May 2, 2007 EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 TiGenix: Transparency notification pursuant to Article 14 of the Law of May 2, 2007 REGULATED INFORMATION PRESS RELEASE Transparency notification pursuant to Article 14 of the Law of May 2, 2007 Leuven (Belgium) - January 18, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix") publishes today a transparency notification pursu |
|
| January 17, 2018 |
TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer) 6-K 1 f6k011618.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2018 Commission File Number: 001-37965 TiGenix (Translation of registrant's name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal |
|
| January 17, 2018 |
TiGenix: Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 EdgarFiling EXHIBIT 99.1 TiGenix: Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 REGULATED INFORMATION PRESS RELEASE Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 Leuven (Belgium) - January 16, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix") announced today that it received transparency notifications pursuant t |
|
| January 16, 2018 |
EdgarFiling EXHIBIT 99.1 TiGenix announces publication in Gastroenterology of 52-week results of the Phase III ADMIRE-CD trial of Cx601 PRESS RELEASE TiGenix announces publication in Gastroenterology of 52-week results of the Phase III ADMIRE-CD trial of Cx601 Leuven (BELGIUM) - January 15, 2018, 07:00 CET - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focu |
|
| January 16, 2018 |
TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2018 Commission File Number: 001-37965 TiGenix (Translation of registrant's name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate b |
|
| January 16, 2018 |
Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 EdgarFiling EXHIBIT 99.1 Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 REGULATED INFORMATION PRESS RELEASE Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 Leuven (Belgium) - January 12, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix") announced today that it received transparency notifications pursuant to Article |
|
| January 16, 2018 |
TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2018 Commission File Number: 001-37965 TiGenix (Translation of registrant's name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate b |
|
| January 12, 2018 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 TiGenix (Name of Subject Company) TiGenix (Name of Person(s) Filing Statement) Ordinary shares, no nominal value (?Shares?) American Depositary Shares (?ADSs?), each representing 20 Shares Warrants to acquire Sha |
|
| January 12, 2018 |
Q&A in respect of Takeda’s intention to acquire TiGenix January 12, 2018 EX-99.1 2 a18-23062ex99d1.htm EX-99.1 Exhibit 99.1 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO, OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION. Q&A in respect of Takeda’s intention to acquire TiGenix January 12, 2018 A. DEAL RATIONALE AND TERMS 1. Why does Takeda intend to acquire TiGenix? We cannot com |
|
| January 12, 2018 |
TiGenix: Transparency Information EdgarFiling EXHIBIT 99.1 TiGenix: Transparency Information PRESS RELEASE REGULATED INFORMATION Transparency Information Leuven (BELGIUM) - January 11, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG) publishes information in accordance with articles 15 and 18 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to t |
|
| January 12, 2018 |
TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2018 Commission File Number: 001-37965 TiGenix (Translation of registrant's name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate b |
|
| January 12, 2018 |
EX-99.5 Exhibit 5 IRREVOCABLE UNDERTAKING The undersigned, (the “Director”); 1. Ownership The Director represents and warrants as follows on the date of this irrevocable undertaking (hereinafter referred to as the “Undertaking”): (a) The Director owns shares in TiGenix NV (hereinafter referred to as the “Shares”, as such number may increase from time to time as the result of any exercises of Warra |
|
| January 12, 2018 |
TGXSF / Tigenix Sa / TAKEDA PHARMACEUTICAL CO LTD - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* TiGenix (Name of Issuer) Ordinary shares, no nominal value (“Shares”) American Depositary Shares (“ADSs”), each representing 20 Shares (Title of Class of Securities) ISIN BE0003864817 (Shares) CUSIP 88675R109 (ADSs) (CUSIP Number) James Kehoe Taked |
|
| January 12, 2018 |
EX-99.3 4 d521799dex993.htm EX-99.3 Exhibit 3 IRREVOCABLE UNDERTAKING The undersigned, 1. Gri-Cel, S.A., a company under the laws of Spain, having its registered office at Avenida de la Generalitat 152, 08174 Sant Cugat del Vallès, Barcelona, Spain, here validly represented by Alfredo Arroyo Guerra, acting in his capacity of Chief Financial Officer, hereinafter referred to as “Gri-Cel”; and 2. Gri |
|
| January 12, 2018 |
EX-99.6 Exhibit 6 AGREEMENT OF JOINT FILING This joint filing agreement (this “Agreement”) is made and entered into as of this 12th day of January, 2018, by and among Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals International AG, Takeda Pharma A/S, Takeda A/S and Takeda Europe Holdings B.V. The parties to this Agreement hereby agree to prepare jointly and file timely (and otherwis |
|
| January 12, 2018 |
EX-99.10 Exhibit 10 POWER OF ATTORNEY Know all by these present, that Takeda A/S, a stock limited company incorporated under the laws of Denmark, and with business address at Dybendal Alle 10, 2630 Taastrup, Denmark (“Takeda A/S”) hereby constitutes and appoints each of Paul Sundberg, Chad Diehl and Brett Budzinski, signing singly, as Takeda A/S’s true and lawful attorney-in-fact to: (1) prepare, |
|
| January 12, 2018 |
EX-99.4 5 d521799dex994.htm EX-99.4 Exhibit 4 IRREVOCABLE UNDERTAKING The undersigned, (the “Director”); 1. Ownership The Director represents and warrants as follows on the date of this irrevocable undertaking (hereinafter referred to as the “Undertaking”): (a) The Director owns shares in TiGenix NV (hereinafter referred to as the “Shares”, as such number may increase from time to time as the resu |
|
| January 12, 2018 |
EX-99.8 9 d521799dex998.htm EX-99.8 Exhibit 8 POWER OF ATTORNEY Know all by these present, that Takeda Pharmaceuticals International AG, a public limited company incorporated under the laws of Switzerland, registered with the commercial register of Canton Zurich under CHE-113.444.401 and with business address at Thurgauerstrasse 130, 8152 Glattpark - Opfikon (Zurich) (“TPIZ”) hereby constitutes an |
|
| January 12, 2018 |
EX-99.7 Exhibit 7 POWER OF ATTORNEY Know all by these present, that Takeda Pharmaceutical Company Limited (the “Reporting Person”) hereby constitutes and appoints each of Paul Sundberg, Chad Diehl and Brett Budzinski, signing singly, as the Reporting Person’s true and lawful attorney-in-fact to: (1) prepare, execute in the Reporting Person’s name and on the Reporting Person’s behalf, and submit to |
|
| January 12, 2018 |
EX-99.1 Exhibit 1 OFFER AND SUPPORT AGREEMENT BETWEEN 1. Takeda Pharmaceutical Company Limited, a company under the laws of Japan, having its registered office at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka, Japan, hereby validly represented by Misako Hirose, in her capacity as Authorised Representative, hereinafter referred to as the “Bidder” or “Takeda”; ON THE ONE HAND AND 2. TiGenix NV, a limited |
|
| January 12, 2018 |
CONFIDENTIAL DISCLOSURE AGREEMENT EX-99.2 3 d521799dex992.htm EX-99.2 Exhibit 2 CONFIDENTIAL DISCLOSURE AGREEMENT This Agreement is made effective as of the date (the “Effective Date”) of the last signature hereto by and between: TiGenix SAU, with registered office at Calle Marconi 1, Parque Tecnologico de Madrid, Tres Cantos, 28760 Madrid, Spain, registered with the Commercial Registry of Madrid under volume number 20117, page 81 |
|
| January 12, 2018 |
EX-99.9 10 d521799dex999.htm EX-99.9 Exhibit 9 POWER OF ATTORNEY Know all by these present, that Takeda Pharma A/S, a stock limited company incorporated under the laws of Denmark, and with business address at Dybendal Alle 10, 2630 Taastrup, Denmark (“Takeda Pharma A/S”) hereby constitutes and appoints each of Paul Sundberg, Chad Diehl and Brett Budzinski, signing singly, as Takeda Pharma A/S’s tr |
|
| January 12, 2018 |
EX-99.11 Exhibit 11 POWER OF ATTORNEY Know all by these present, that Takeda Europe Holdings B.V., a private limited liability company incorporated under the laws of the Netherlands, and with a business address at Jupiterstraat 250, 2132 HK Hoofddorp, Netherlands (“Takeda Europe”) hereby constitutes and appoints each of Paul Sundberg, Chad Diehl and Brett Budzinski, signing singly, as Takeda Europ |
|
| January 10, 2018 |
TGXSF / Tigenix Sa 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2017 Commission File Number 001-37965 TiGenix Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or wil |
|
| January 10, 2018 |
Exhibit 99.1 PRESS RELEASE REGULATED INFORMATION Transparency Information Leuven (BELGIUM) - November 30, 2017, 22:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG) publishes information in accordance with articles 15 and 18 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including va |
|
| January 8, 2018 |
EX-99.1 Driving Profitable Growth Takeda Pharmaceutical Company Christophe Weber President & Chief Executive Officer 36 Annual J.P. Morgan Healthcare Conference January 8, 2018 Exhibit 99.1 th 2 Important Notice Forward-Looking Statements This presentation contains forward-looking statements regarding Takedas future business, financial position and results of operations, including estimates, fore |
|
| January 8, 2018 |
TKPYY / Takeda Pharmaceutical Co., Ltd. SC TO-C SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 TiGenix (Name of Subject Company (Issuer)) TAKEDA PHARMACEUTICAL COMPANY LIMITED (Name of Filing Persons (Offeror)) Ordinary shares, no nominal value (Shares) American Depositary Shares (ADSs), each re |
|
| January 8, 2018 |
Exhibit 2 IRREVOCABLE UNDERTAKING The undersigned, 1. Gri-Cel, S.A., a company under the laws of Spain, having its registered office at Avenida de la Generalitat 152, 08174 Sant Cugat del Vallès, Barcelona, Spain, here validly represented by Alfredo Arroyo Guerra, acting in his capacity of Chief Financial Officer, hereinafter referred to as “Gri-Cel”; and 2. Grifols Worldwide Operations Ltd., a co |
|
| January 8, 2018 |
ARDM / Aradigm Corp. / Grifols SA - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934* TiGenix (Name of Issuer) Ordinary shares, no nominal value per share (Title of Class of Securities) 88675R 10 9 (CUSIP Number) Grifols, S.A. Avinguda de la Generalitat, 152-158 Parc de Negocis Can Sant Joan Sant Cugat del Valles 08174, Barcelona, Spain Tel: +34 93 571 050 |
|
| January 8, 2018 |
Exhibit 1 JOINT FILING AGREEMENT The persons below hereby agree that the Schedule 13D to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13D, shall be filed jointly on behalf of each of them. |
|
| January 5, 2018 |
EX-99.3 4 d520985dex993.htm EX-99.3 Exhibit 99.3 The potential acquisition of TiGenix would build on Takeda’s late stage pipeline and leadership in gastroenterology. Read important information here: http://bit.ly/2IWqluk [Image and quote of Dr. Asit Parikh embedded in Tweet] “This potential acquisition is a natural extension of an existing partnership agreement between Takeda and TiGenix, which ai |
|
| January 5, 2018 |
EX-99.2 3 d520985dex992.htm EX-99.2 Exhibit 99.2 Takeda is excited to announce our intention to acquire TiGenix. Read important information here: http://bit.ly/2IWqluk |
|
| January 5, 2018 |
TKPYY / Takeda Pharmaceutical Co., Ltd. SC TO-C SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 TiGenix (Name of Subject Company (Issuer)) TAKEDA PHARMACEUTICAL COMPANY LIMITED (Name of Filing Persons (Offeror)) Ordinary shares, no nominal value (?Shares?) American Depositary Shares (?ADSs?), each re |
|
| January 5, 2018 |
EX-99.1 Exhibit 99.1 @TakedaPharma Potential acquisition of @TiGenix would build on our late stage pipeline and leadership in gastroenterology. Read important information here: bit.ly/2IWqluk [Image and quote of Dr. Asit Parikh embedded in Tweet] ?This potential acquisition is a natural extension of an existing partnership agreement between Takeda and TiGenix, which aims to bring new treatment opt |
|
| January 5, 2018 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 TiGenix (Name of Subject Company) TiGenix (Name of Person(s) Filing Statement) Ordinary shares, no nominal value (?Shares?) American Depositary Shares (?ADSs?), each representing 20 Shares Warrants to acquire Sha |
|
| January 5, 2018 |
Takeda - TiGenix Acquisition Frequently Asked Questions (FAQs) for Employees Exhibit 99.2 Takeda - TiGenix Acquisition Frequently Asked Questions (FAQs) for Employees This FAQ document was developed to help inform TiGenix employees about the proposed take-over by Takeda. This document is for internal use only and should not be distributed or used externally. Any inquiries that you receive from reporters, analysts, business partners or other parties should be forwarded to C |
|
| January 5, 2018 |
email from the ceo of the company to employees of the company, dated january 5, 2018 EX-99.1 2 a18-23061ex99d1.htm EX-99.1 Exhibit 99.1 email from the ceo of the company to employees of the company, dated january 5, 2018 Dear all, You have probably seen that earlier this morning Takeda announced its intention to launch a bid to acquire TiGenix. A few minutes later we issued another press release in which we acknowledged the intention of Takeda and informed the market of the suppor |
|
| January 5, 2018 |
TGXSF / Tigenix Sa 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2018 Commission File Number 001-37965 TiGenix Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or will |
|
| January 5, 2018 |
Takeda announces its intention to acquire TiGenix Exhibit 99.1 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO, OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION. PRESS RELEASE REGULATED INFORMATION INSIDE INFORMATION Communication in accordance with section 8, ?1 of the Belgian Royal Decree of 27 April 2007 on public takeover bids Takeda announces its intent |
|
| January 5, 2018 |
EX-99.1 Exhibit 99.1 Communication in accordance with article 8, ?1 of the Belgian Royal Decree of 27 April 2007 on public takeover bids. Takeda announces intention to launch a potential voluntary and conditional public takeover bid for all shares, warrants, American Depositary Shares and convertible bonds of TiGenix Osaka, Japan, January 5, 2018, 07:00 CET/15:00 JST ? Takeda Pharmaceutical Compan |
|
| January 5, 2018 |
TKPYY / Takeda Pharmaceutical Co., Ltd. SC TO-C SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 TiGenix (Name of Subject Company (Issuer)) TAKEDA PHARMACEUTICAL COMPANY LIMITED (Name of Filing Persons (Offeror)) Ordinary shares, no nominal value (?Shares?) American Depositary Shares (?ADSs?), each re |
|
| January 5, 2018 |
EX-99.3 4 d501689dex993.htm EX-99.3 Exhibit 99.3 @TakedaPharma We are excited to announce our intention to acquire @TiGenix. Read important information here: bit.ly/2IWqluk |
|
| January 5, 2018 |
EX-99.2 Exhibit 99.2 Takeda Announces Intention to Acquire TiGenix Expands Takeda?s Late Stage Pipeline and Leadership in Gastroenterology Acquisition Highlights ? Deal reinforces Takeda?s commitment to patients living with Inflammatory Bowel Disease (IBD), an area of high unmet medical need ? Acquisition extends existing collaboration between Takeda and TiGenix to develop and commercialize Cx601 |
|
| January 4, 2018 |
TiGenix confirms strategic focus on Cx601 and its adipose derived stem cell (eASC) platform Exhibit 99.1 PRESS RELEASE TiGenix confirms strategic focus on Cx601 and its adipose derived stem cell (eASC) platform Leuven (BELGIUM) - December 20, 2017, 7:00h CET - TiGenix NV (Euronext Brussels and NASDAQ: TIG) (TiGenix or the Company), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel |
|
| January 4, 2018 |
TGXSF / Tigenix Sa 6-K (Current Report of Foreign Issuer) 6-K 1 a18-224516k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2017 Commission File Number 001-37965 TiGenix Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether t |
|
| January 4, 2018 |
Transparency notification pursuant to Article 14 of the Law of May 2, 2007 EdgarFiling EXHIBIT 99.1 Transparency notification pursuant to Article 14 of the Law of May 2, 2007 REGULATED INFORMATION PRESS RELEASE Transparency notification pursuant to Article 14 of the Law of May 2, 2007 Leuven (Belgium) - January 3, 2018, 22:00h CEST - TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix") publishes today a transparency notification pursuant to Article 14 of the Belgian |
|
| January 4, 2018 |
TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2018 Commission File Number: 001-37965 TiGenix (Translation of registrant's name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate b |
|
| December 22, 2017 |
EX-99.1 2 a17-288911ex99d1.htm EX-99.1 Exhibit 99.1 CONDENSED CONSOLIDATED INCOME STATEMENTS (UNAUDITED) SIX-MONTH PERIOD ENDED JUNE 30, Thousands of euros (€), except for share data (in euros) 2017 2016 CONSOLIDATED INCOME STATEMENTS Revenues Royalties — 293 Grants and other operating income 588 650 Total revenues and other operating income 588 943 Research and development expenses (16,637 ) (9,7 |
|
| December 22, 2017 |
TGXSF / Tigenix Sa 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2017 Commission File Number 001-37965 TiGenix Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or wil |
|
| December 21, 2017 |
TGXSF / Tigenix Sa 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2017 Commission File Number 001-37965 TiGenix Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or wi |
|
| December 21, 2017 |
TiGenix Financial Half — Year Results 2017 Exhibit 99.1 TiGenix Financial Half Year Results 2017 Financial Highlights for the first half 2017 During the first half of 2017, total revenues amounted to EUR 0.6 million compared to EUR 0.9 million to the same period in 2016. This slight decrease is related to the reduction in royalties and other operating income following the Companys decision to withdraw the market authorization for Chondr |
|
| December 15, 2017 |
TGXSF / Tigenix Sa 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2017 Commission File Number 001-37965 TiGenix Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or wil |
|
| December 15, 2017 |
Exhibit 99.1 PRESS RELEASE REGULATED INFORMATION INSIDE INFORMATION Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn?s disease ? First allogeneic stem cell therapy to receive positive CHMP opinion in Europe ? Cx601 offers potential new treatment option for patients who do not respond to current available therapi |
|
| December 15, 2017 |
TGXSF / Tigenix Sa 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2017 Commission File Number 001-37965 TiGenix Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or wil |
|
| December 15, 2017 |
Exhibit 99.1 PRESS RELEASE REGULATED INFORMATION INSIDE INFORMATION Mesoblast grants TiGenix an exclusive global patent license to use adipose-derived mesenchymal stem cells in the local treatment of fistulae New York, USA, Melbourne, Australia and Leuven, Belgium, December 14, 2017, 23:55h CET - Mesoblast Limited (ASX: MSB; Nasdaq: MESO) and TiGenix NV (Euronext Brussels and Nasdaq: TIG) today an |
|
| November 30, 2017 |
JPMorgan Chase & Co notifies 3.12% shareholding in TiGenix EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 JPMorgan Chase & Co notifies 3.12% shareholding in TiGenix Leuven (Belgium) - November 24, 2017, 22:00h CEST -TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix") publishes today a transparency notification pursuant to Article 14 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitte |
|
| November 30, 2017 |
TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2017 Commission File Number: 001-37965 TiGenix (Translation of registrant's name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate |
|
| November 20, 2017 |
TiGenix to present positive 52-week Phase III Cx601 data at EHA-SWG Scientific Meeting EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 PRESS RELEASE TiGenix to present positive 52-week Phase III Cx601 data at EHA-SWG Scientific Meeting Leuven (BELGIUM) - November 20, 2017, 07:00h CET - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop nove |
|
| November 20, 2017 |
TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2017 Commission File Number: 001-37965 TiGenix (Translation of registrant's name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate |
|
| November 17, 2017 |
TGXSF / Tigenix Sa 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2017 Commission File Number 001-37965 TiGenix Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or wil |
|
| November 17, 2017 |
Exhibit 99.1 PRESS RELEASE TiGenix announces approval of trade name for lead development candidate Cx601 in Europe International Nonproprietary Name (INN), darvadstrocel, approved for Cx601 Leuven (BELGIUM) - November 16, 2017, 7h:00 CET - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or d |
|
| November 6, 2017 |
TGXSF / Tigenix Sa 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2017 Commission File Number 001-37965 TiGenix Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or wil |
|
| November 6, 2017 |
TiGenix announces partial conversion of bonds EX-99.1 2 a17-260441ex99d1.htm EX-99.1 Exhibit 99.1 PRESS RELEASE TiGenix announces partial conversion of bonds Leuven (BELGIUM) - November 6, 2017, 7:00h CET - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical conditi |
|
| November 2, 2017 |
Tigenix 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2017 Commission File Number 001-37965 TiGenix Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or wil |
|
| November 2, 2017 |
TiGenix strengthens European IP protection around lead development program Cx601 Exhibit 99.1 PRESS RELEASE TiGenix strengthens European IP protection around lead development program Cx601 Leuven (BELGIUM) - November 2, 2017, 07:00h CET - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical conditions |
|
| October 31, 2017 |
Tigenix 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2017 Commission File Number 001-37965 TiGenix Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or will |
|
| October 31, 2017 |
TiGenix to host Analyst and Investor Event in New York City EX-99.1 2 a17-249201ex99d1.htm EX-99.1 Exhibit 99.1 PRESS RELEASE TiGenix to host Analyst and Investor Event in New York City Leuven (BELGIUM) - October 2, 2017, 07:00h CET - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious m |
|
| October 31, 2017 |
TiGenix granted Orphan Drug Designation from the U.S. FDA for Cx601 EX-99.3 4 a17-249201ex99d3.htm EX-99.3 Exhibit 99.3 PRESS RELEASE TiGenix granted Orphan Drug Designation from the U.S. FDA for Cx601 Leuven (BELGIUM) - October 23, 2017, 7:00h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for |
|
| October 31, 2017 |
EX-99.2 3 a17-249201ex99d2.htm EX-99.2 Exhibit 99.2 PRESS RELEASE TiGenix to present positive 52-week Phase III results of Cx601 at World Congress of Gastroenterology at ACG 2017 meeting Leuven (BELGIUM) - October 5, 2017, 07:00h CET - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor |
|
| October 31, 2017 |
TiGenix provides regulatory update on Cx601 EU Marketing Authorization Application procedure EX-99.4 5 a17-249201ex99d4.htm EX-99.4 Exhibit 99.4 PRESS RELEASE TiGenix provides regulatory update on Cx601 EU Marketing Authorization Application procedure Leuven (BELGIUM) - October 31, 2017, 7:00h CET - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to deve |
|
| September 21, 2017 |
TiGenix Financial Half Year Results 2017 Exhibit 99.1 TiGenix Financial Half ? Year Results 2017 Financial Highlights for the first half 2017 During the first half of 2017, total revenues amounted to EUR 0.6 million compared to EUR 0.9 million to the same period in 2016. This slight decrease is related to the reduction in royalties and other operating income following the Company?s decision to withdraw the market authorization for Chondr |
|
| September 21, 2017 |
Tigenix 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2017 Commission File Number 001-37965 TiGenix Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or wi |
|
| September 19, 2017 |
Tigenix 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2017 Commission File Number 001-37965 TiGenix Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or wi |
|
| September 19, 2017 |
Exhibit 99.1 PRESS RELEASE REGULATED INFORMATION TiGenix Business and Financial Update for the First Half 2017 (Conference call and webcast today at 15:00 CET) Leuven (BELGIUM) September 19, 2017, 07:00h CET TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to |
|
| September 14, 2017 |
Tigenix 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2017 Commission File Number 001-37965 TiGenix Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or wi |
|
| September 14, 2017 |
Exhibit 99.1 PRESS RELEASE TiGenix strengthens US operations with senior appointments - Dr. Gregory Gordon appointed as Head of Medical Department (U.S.) - Annette Valles-Sukkar appointed as Associate Director, Clinical Project Leuven (BELGIUM) - September 12, 2017, 7:00h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company exploiting the anti-inflammatory p |
|
| September 6, 2017 |
Tigenix 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2017 Commission File Number 001-37965 TiGenix Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or wi |
|
| September 6, 2017 |
EX-99.1 2 a17-213971ex99d1.htm EX-99.1 Exhibit 99.1 PRESS RELEASE TiGenix obtains commercial production license for expanded manufacturing facility - Provides capacity for potential European commercial roll out of investigational stem cell therapy, Cx601 - Expanded facility also secures manufacturing for other pipeline products Leuven (BELGIUM) - September 05, 2017, 7:00h CEST - TiGenix NV (Eurone |
|
| July 31, 2017 |
Tigenix 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2017 Commission File Number 001-37965 TiGenix Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or will fi |
|
| July 31, 2017 |
EX-99.1 2 a17-185361ex99d1.htm EX-99.1 Exhibit 99.1 PRESS RELEASE REGULATED INFORMATION Transparency Information Leuven (BELGIUM) — July 28, 2017, 22:01h CET — TiGenix NV (Euronext Brussels and Nasdaq: TIG) publishes information in accordance with articles 15 and 18 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on |
|
| July 13, 2017 |
TGXSF / Tigenix Sa / Grifols SA - SCHEDULE 13G Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* TiGenix (Name of Issuer) ordinary shares, no nominal value per share (Title of Class of Securities) 88675R 10 9 (CUSIP Number) December 20, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| June 20, 2017 |
Exhibit 99.1 PRESS RELEASE Takeda and TiGenix announce that Swissmedic has accepted for review the file on Cx601 for the treatment of complex perianal fistulas in Crohn?s disease patients Pf?ffikon, SZ, June 20, 2017, and Leuven, Belgium, June 20, 2017 - Takeda Pharma AG (TSE: 4502) (?Takeda?) and TiGenix NV (Euronext Brussels and Nasdaq: TIG) (?TiGenix?) today announced that the Swiss Agency for |
|
| June 20, 2017 |
Tigenix 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2017 Commission File Number 001-37965 TiGenix Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or will fi |
|
| June 15, 2017 |
Tigenix 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2017 Commission File Number 001-37965 TiGenix Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or will fi |
|
| June 15, 2017 |
EX-99.1 2 a17-153042ex99d1.htm EX-99.1 Exhibit 99.1 PRESS RELEASE TiGenix Partners with U.S. and European Patient Advocacy Groups Focused on Crohn’s Disease and Ulcerative Colitis - Joins the Crohn’s and Colitis Foundation’s President’s Corporate Circle - Signs Sponsorship Agreement with the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA) Leuven (BELGIUM) - June 15th, 20 |
|
| June 15, 2017 |
TiGenix Launches Global Phase III Trial for Cx601 EX-99.1 2 a17-153041ex99d1.htm EX-99.1 Exhibit 99.1 PRESS RELEASE TiGenix Launches Global Phase III Trial for Cx601 Leuven (BELGIUM) - June 13, 2017, 07:00h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical cond |
|
| June 15, 2017 |
Tigenix 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2017 Commission File Number 001-37965 TiGenix Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or will fi |
|
| June 12, 2017 |
Tigenix 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2017 Commission File Number 001-37965 TiGenix Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or will fi |
|
| June 12, 2017 |
TiGenix announces final equity payment for cardiac platform acquisition EX-99.1 2 a17-150831ex99d1.htm EX-99.1 Exhibit 99.1 PRESS RELEASE REGULATED INFORMATION TiGenix announces final equity payment for cardiac platform acquisition Leuven (BELGIUM) - June 12, 2017, 07:00h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to deve |
|
| June 1, 2017 |
TiGenix to present at the Jefferies 2017 Global Healthcare Conference in New York EX-99.1 2 a17-146251ex99d1.htm EX-99.1 Exhibit 99.1 PRESS RELEASE TiGenix to present at the Jefferies 2017 Global Healthcare Conference in New York Leuven (BELGIUM) - June 1, 2017, 07:00h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel the |
|
| June 1, 2017 |
Tigenix 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2017 Commission File Number 001-37965 TiGenix Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or will fi |
|
| May 31, 2017 |
TiGenix provides regulatory update on Cx601 EU Marketing Authorization Application procedure Exhibit 99.1 PRESS RELEASE TiGenix provides regulatory update on Cx601 EU Marketing Authorization Application procedure Leuven (BELGIUM) - May 31, 2017, 07:00h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical c |
|
| May 31, 2017 |
Tigenix 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2017 Commission File Number 001-37965 TiGenix Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or will fil |
|
| May 12, 2017 |
Tigenix 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2017 Commission File Number 001-37965 TiGenix Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or will fil |
|
| May 12, 2017 |
Exhibit 99.1 TiGenix Naamloze vennootschap die een openbaar beroep doet of heeft gedaan op het spaarwezen Romeinse straat 12 box 2 3001 Leuven VAT BE 0471.340.123 RLE Leuven CONVENING NOTICE TO THE EXTRAORDINARY SHAREHOLDERS MEETING TO BE HELD ON 1 JUNE 2017 The board of directors of TiGenix NV (the Company) is pleased to invite you to the extraordinary shareholders meeting of TiGenix NV that |
|
| May 11, 2017 |
Tigenix 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2017 Commission File Number 001-37965 TiGenix Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or will fil |
|
| May 11, 2017 |
TiGenix to present at Bank of America Merrill Lynch 2017 Healthcare Conference in Las Vegas Exhibit 99.1 PRESS RELEASE TiGenix to present at Bank of America Merrill Lynch 2017 Healthcare Conference in Las Vegas Leuven (BELGIUM) - May 11, 2017, 07:00h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical co |
|
| May 10, 2017 |
Tigenix 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2017 Commission File Number 001-37965 TiGenix Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or will fil |
|
| May 10, 2017 |
EX-99.1 2 a17-128701ex99d1.htm EX-99.1 Exhibit 99.1 PRESS RELEASE TiGenix to present at the Crohn’s and Colitis Foundation’s Novel Technologies in Inflammatory Bowel Disease workshop in New York Leuven (BELGIUM) - May 10, 2017, 07:00h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or |
|
| May 4, 2017 |
TiGenix Cx601 positive long-term results to be presented at Digestive Disease Week Exhibit 99.1 PRESS RELEASE TiGenix Cx601 positive long-term results to be presented at Digestive Disease Week Leuven (BELGIUM) - May 4, 2017, 07:00h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical conditions, |
|
| May 4, 2017 |
Tigenix 6-K (Current Report of Foreign Issuer) 6-K 1 a17-1246516k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2017 Commission File Number 001-37965 TiGenix Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the r |
|
| May 2, 2017 |
EX-99.1 2 a17-122711ex99d1.htm EX-99.1 Exhibit 99.1 TiGenix Naamloze vennootschap die een openbaar beroep doet of heeft gedaan op het spaarwezen Romeinse straat 12 box 2 3001 Leuven VAT BE 0471.340.123 RLE Leuven CONVENING NOTICE TO THE ANNUAL SHAREHOLDERS’ MEETING TO BE HELD ON 1 JUNE 2017 The board of directors of TiGenix NV (the “Company”) is pleased to invite you to the annual shareholders’ me |
|
| May 2, 2017 |
Tigenix 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2017 Commission File Number 001-37965 TiGenix Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or will fil |
|
| April 7, 2017 |
Exhibit 99.1 TiGenix Naamloze vennootschap die een openbaar beroep doet of heeft gedaan op het spaarwezen Romeinse straat 12 box 2 3001 Leuven VAT BE 0471.340.123 RLE Leuven CONVENING NOTICE TO THE EXTRAORDINARY SHAREHOLDERS MEETING TO BE HELD ON 9 MAY 2017 The board of directors of TiGenix NV (the Company) is pleased to invite you to the extraordinary shareholders meeting of TiGenix NV that w |
|
| April 7, 2017 |
Tigenix 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2017 Commission File Number 001-37965 TiGenix Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or will f |
|
| April 6, 2017 |
20-F 1 dp7478820f.htm FORM 20-F As filed with the Securities and Exchange Commission on April 6, 2017 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal yea |
|
| April 6, 2017 |
Tigenix 6-K (Current Report of Foreign Issuer) 6-K 1 a17-1101016k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2017 Commission File Number 001-37965 TiGenix Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the |
|
| April 6, 2017 |
TiGenix reports 2016 full year results (Conference call and webcast today at 13:00 CEST) Exhibit 99.1 PRESS RELEASE REGULATED INFORMATION INSIDER INFORMATION TiGenix reports 2016 full year results (Conference call and webcast today at 13:00 CEST) Leuven (BELGIUM) April 6, 2017, 07:00h CEST TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company developing and commercializing novel therapeutics which exploit the anti-inflammatory properties of allogene |
|
| April 5, 2017 |
TiGenix to participate in key investor conferences in April 2017 Exhibit 99.1 PRESS RELEASE TiGenix to participate in key investor conferences in April 2017 Leuven (BELGIUM) - April 5, 2017, 07:00h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company developing and commercializing novel therapeutics which exploit the anti-inflammatory properties of allogeneic, or donor-derived, stem cells, today announces that its managem |
|
| April 5, 2017 |
Tigenix 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2017 Commission File Number 001-37965 TiGenix Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or will f |
|
| March 13, 2017 |
Tigenix 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2017 Commission File Number 001-37965 TiGenix Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or will f |
|
| March 13, 2017 |
TiGenix Announces Top-Line Phase I/II Results of AlloCSC-01 in Acute Myocardial Infarction EX-99.1 2 a17-82211ex99d1.htm EX-99.1 Exhibit 99.1 PRESS RELEASE REGULATED INFORMATION INSIDE INFORMATION TiGenix Announces Top-Line Phase I/II Results of AlloCSC-01 in Acute Myocardial Infarction Leuven (BELGIUM) - March 13, 2017, 07:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG), an advanced biopharmaceutical company focused on developing novel therapeutics from its two proprietary pla |
|
| March 9, 2017 |
Tigenix 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2017 Commission File Number 001-37965 TiGenix Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or will f |
|
| March 9, 2017 |
TiGenix Announces Positive Topline Week-104 Data for Cx601 ADMIRE-CD Trial EX-99.1 2 a17-80591ex99d1.htm EX-99.1 Exhibit 99.1 PRESS RELEASE TiGenix Announces Positive Topline Week-104 Data for Cx601 ADMIRE-CD Trial Leuven (BELGIUM) - 9th March, 2017, 7:00 am CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG), an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic stem cells, today |
|
| March 7, 2017 |
TiGenix Receives Positive Feedback from the FDA on Cx601 Global Phase III Trial Protocol Exhibit 99.1 PRESS RELEASE TiGenix Receives Positive Feedback from the FDA on Cx601 Global Phase III Trial Protocol Leuven (BELGIUM) - 7th March, 2017, 7:00 am CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG), an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platform of allogeneic stem cells, announced today that it has rec |
|
| March 7, 2017 |
Tigenix 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2017 Commission File Number 001-37965 TiGenix Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or will f |
